API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.targetedonc.com/view/arfolitixorin-lands-fda-fast-track-designation-for-advanced-crc
https://www.prnewswire.com/news-releases/invitation-to-a-conference-call-and-webcast-by-isofol-in-connection-with-the-entered-license-agreement-for-paladin-labs-inc-to-commercialize-arfolitixorin-in-canada-301164819.html
https://www.biospace.com/article/releases/isofol-announces-licensing-agreement-for-paladin-labs-inc-to-commercialize-arfolitixorin-in-canada/#:~:text=The%20license%20agreement%20is%20focused,retain%20all%20international%20development%20rights.
https://isofolmedical.com/isofol-enters-licensing-agreement-with-solasia-to-develop-and-commercialize-arfolitixorin-in-japan/
https://www.prnewswire.com/news-releases/isofol-enters-licensing-agreement-with-solasia-to-develop-and-commercialize-arfolitixorin-in-japan-301111582.html
https://www.prnewswire.com/news-releases/isofols-drug-candidate-arfolitixorin-receives-additional-clinical-patent-approval-in-the-united-states-301052612.html
https://www.prnewswire.com/news-releases/the-first-patient-included-in-japan-in-isofols-phase-3-agent-study-301006698.html